Regenerx Biopharmaceuticals Inc (RGRX)
0.0014
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Regenerx Biopharmaceuticals Net Income (TTM): -1.689M for March 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2023 | -1.689M |
| December 31, 2022 | -1.728M |
| September 30, 2022 | -1.786M |
| June 30, 2022 | -1.850M |
| March 31, 2022 | -1.642M |
| December 31, 2021 | -1.598M |
| September 30, 2021 | -1.516M |
| June 30, 2021 | -1.419M |
| March 31, 2021 | -1.516M |
| December 31, 2020 | -1.523M |
| September 30, 2020 | -1.505M |
| June 30, 2020 | -1.506M |
| March 31, 2020 | -1.458M |
| December 31, 2019 | -1.404M |
| September 30, 2019 | -1.319M |
| June 30, 2019 | -1.361M |
| March 31, 2019 | -1.340M |
| December 31, 2018 | -1.994M |
| September 30, 2018 | -0.3123M |
| June 30, 2018 | -1.295M |
| March 31, 2018 | -0.8087M |
| December 31, 2017 | 0.2865M |
| September 30, 2017 | -0.7089M |
| June 30, 2017 | 1.511M |
| March 31, 2017 | 3.717M |
| Date | Value |
|---|---|
| December 31, 2016 | 0.2291M |
| September 30, 2016 | -0.8532M |
| June 30, 2016 | -2.844M |
| March 31, 2016 | -6.931M |
| December 31, 2015 | -5.270M |
| September 30, 2015 | -5.143M |
| June 30, 2015 | -3.890M |
| March 31, 2015 | -2.347M |
| December 31, 2014 | -2.754M |
| September 30, 2014 | -2.229M |
| June 30, 2014 | -2.453M |
| March 31, 2014 | -2.464M |
| December 31, 2013 | -0.6713M |
| September 30, 2013 | -0.7603M |
| June 30, 2013 | -0.7549M |
| March 31, 2013 | -0.7505M |
| December 31, 2012 | -0.847M |
| September 30, 2012 | -1.610M |
| June 30, 2012 | -3.533M |
| March 31, 2012 | -4.840M |
| December 31, 2011 | -6.007M |
| September 30, 2011 | -6.066M |
| June 30, 2011 | -5.636M |
| March 31, 2011 | -5.475M |
| December 31, 2010 | -5.024M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-1.850M
Minimum
Jun 2022
-1.319M
Maximum
Sep 2019
-1.551M
Average
-1.516M
Median
Net Income (TTM) Benchmarks
| FluoroPharma Medical Inc | -2.050M |
| RenovaCare Inc | -5.744M |
| Xeno Transplants Corp | -- |
| Entia Biosciences Inc | -1.396M |
| OncoVista Innovative Therapies Inc | -3.270M |